{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Table 6:', 'SVdX Treatment: Schedule of Visits for In-clinic Dosing and MM Evaluations', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'Day', 'Cycles', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', '>1', 'X', 'C', 'C', 'C', 'Abbreviations: X = Visit for in-clinic dosing and MM disease assessment; C = Visit for in-clinic dosing only; MM = multiple myeloma; SVd = selinexor plus bortezomib plus', 'low-dose dexamethasone; SVdX = SVd treatment after crossover.', 'Note: SVdX will follow the dose schedule for SVd (Table 8).', 'Table 7:', 'SdX Treatment: Schedule of Visits for In-clinic Dosing and MM Evaluations', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'Day', 'Cycles', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', '>1', 'X', 'Abbreviations: X = Visit for in-clinic dosing and MM disease assessment; MM = multiple myeloma; SdX = selinexor plus low-dose dexamethasone treatment after crossover.', 'Note: SdX will follow the dose schedule in Table 11.', 'Confidential', 'Page 30', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '3.2.', 'Dose Schedules', 'Table 8:', 'SVd Arm/SVdX Treatment Dose Schedule; 5-Week (35-Day) Cycle', 'Week 1', 'Week 2', 'Week 3', 'Week 4', 'Week 5', 'SVd/', 'Day', 'SVdXa', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', '32', '33', '34', '35', 'SVd/SVdX Dose Schedule', 'Selb', 'X', 'Bortc', 'Rest period', 'Dexd', 'X', 'X', 'X', 'X', 'Selinexor Dose Escalation for Cycles >3:', 'Only Considered for Patients in the SVd Arm or on SVdX Treatment Who Meet the Following 3 Criteria: 1) Do Not Achieve At Least a PR Within the', 'First 2 Cycles, 2) Are Tolerating SVd or SVdX Well at Dose Level 0, and 3) Do Not Have Any AEs Related to Study Treatment', 'Grade>2', '(NCI', 'CTCAE V. 4.03) at the Time of Dose Escalation', 'Sele', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Bortc', 'Rest period', 'Dexd', 'X', 'X', 'X', 'X', 'Abbreviations: AE = adverse event; BIW = twice weekly; Bort = bortezomib; BSA = body surface area; CTCAE = Common Terminology Criteria for Adverse Events; D = day;', 'Dex = dexamethasone; eCRF = electronic case report form; MM = multiple myeloma; NCI = National Cancer Institute; PR = partial response: QW = once weekly; SC =', 'subcutaneous; Sel = selinexor; SVd = selinexor plus bortezomib plus low-dose dexamethasone.', \"a If the patient's weight fluctuates substantially from baseline (ie, >20%) during treatment, BSA should be recalculated.\", 'b Selinexor will be given as a fixed oral 100 mg dose QW. In no case may the selinexor dose exceed 70 mg/m\u00b2 per dose for any patient.', 'c Bortezomib will be given at a dose of 1.3 mg/m\u00b2 SC QW during Weeks 1 through 4, followed by a 13-day rest period.', 'd Dexamethasone will be given as an oral 20 mg dose BIW (ie, a total of 40 mg weekly). For patients who develop partial intolerance to glucocorticoids during', 'the study (as determined by the Investigator), a dose reduction to a minimum dose of 10 to 12 mg dexamethasone BIW (ie, a total of 20 to 24 mg weekly) is', \"permitted after a clear documentation of intolerance. Any dose reductions should be documented in the patient's research record and the eCRF.\", 'e', 'Selinexor may be given as a fixed oral 60 mg dose BIW during Weeks 1 through 5 of Cycles >3.', 'Confidential', 'Page 31', 'Version 4.0']\n\n###\n\n", "completion": "END"}